Forest plot of PONV incidence.

<p>Forest plot of PONV incidence.</p

Sensitivity analysis result of EA incidence.

<p>Sensitivity analysis result of EA incidence.</p

Characteristics of included trials.

<p>Characteristics of included trials.</p

Exploring the Effect of Different Secondary Building Units as Lewis Acid Sites in MOF Materials for the CO₂ Cycloaddition Reaction

In order to explore the catalytic effect of different Lewis acid sites (LASs) in the CO2 cycloaddition reaction, different secondary building units and N-rich organic ligand 4,4′,4″-s-triazine-1,3,5-triyltri-p-aminobenzoate were assembled to construct six reported MOF materials: [Cu3(tatab)2(H2O)3]·8DMF·9H2O (1), [Cu3(tatab)2(H2O)3]·7.5H2O (2), [Zn4O(tatab)2]·3H2O·17DMF (3), [In3O(tatab)2(H2O)3](NO3)·15DMA (4), [Zr6O4(OH)7(tatab)(Htatab)3(H2O)3]·xGuest (5), and [Zr6O4(OH)4(tatab)4(H2O)3]·xGuest (6) (DMF = N,N-dimethylformamide, and DMA = N,N-dimethylacetamide). Large pore sizes of compound 2 enhance the concentration of substrates, and the multi-active sites inside its framework synergistically promote the process of the CO2 cycloaddition reaction. Such advantages endow compound 2 with the best catalytic performance among the six compounds and surpass many of the reported MOF-based catalysts. Meanwhile, the comparison of the catalytic efficiency indicated that Cu-paddlewheel and Zn4O display better catalytic performances than In3O and Zr6 cluster. The experiments investigate the catalytic effects of LAS types and prove that it is feasible to improve CO2 fixation property by introducing multi-active sites into MOFs

Forest plot of PACU length of stay.

<p>Forest plot of PACU length of stay.</p

Forest plot of pain incidence.

<p>Forest plot of pain incidence.</p

Forest plot of EA incidence.

<p>Forest plot of EA incidence.</p

Forest plot of emergence time.

<p>Forest plot of emergence time.</p

Funnel plot of EA incidence.

<p>Funnel plot of EA incidence.</p

Risk of bias assessment for evaluation the quality of each included trials.

<p>Risk of bias assessment for evaluation the quality of each included trials.</p